What is the recommended dose of Asmanex (mometasone) for pediatric patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

The recommended starting doses and highest recommended daily dose for ASMANEX TWISTHALER treatment based on prior asthma therapy are provided in Table 1 ... § Recommended pediatric dosage is 110 mcg once daily in the evening regardless of prior therapy Children 4-11 years of age§110 mcg once daily in the evening110 mcg

The recommended dose for pediatric patients (4-11 years of age) is 110 mcg once daily in the evening 1.

From the Research

Asmanex (mometasone furoate) is approved for pediatric patients with asthma in different doses based on age, with a recommended starting dose of 110 mcg once daily in the evening for children 4-11 years old and 220 mcg once daily in the evening for adolescents 12 years and older, which can be increased to a maximum of 440 mcg daily if needed. The dosing should be adjusted to the lowest effective dose once asthma stability is achieved, as indicated by the study 2. Patients should rinse their mouth after each use to reduce the risk of oral thrush. Asmanex is an inhaled corticosteroid that works by reducing inflammation in the airways, which helps prevent asthma symptoms by decreasing swelling and mucus production in the bronchial tubes. Some key points to consider when prescribing Asmanex include:

  • The importance of regular daily use for effectiveness, with improvement seen within 24 hours but optimal benefit taking 1-2 weeks of consistent use, as noted in the study 3.
  • The need for patients to understand that Asmanex is a controller medication for long-term management and not for acute symptom relief.
  • The potential for reduced risk of asthma exacerbations with maintenance on ICS/LABA combination therapy compared to step-down to ICS monotherapy, as shown in the study 2.
  • The lack of significant difference in serious asthma outcomes between patients maintained on ICS/LABA and those who stepped down to ICS monotherapy, as reported in the study 2. Overall, the most recent and highest quality study 2 supports the use of Asmanex in pediatric patients with asthma, with careful consideration of dosing and potential benefits and risks.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.